Myeloid sarcoma of the vulva as the initial presentation of acute myeloid leukaemia

2015 ◽  
Vol 174 (1) ◽  
pp. 234-236 ◽  
Author(s):  
S.C.‐S. Hu ◽  
W.‐T. Chen ◽  
G.‐S. Chen

2019 ◽  
Vol 11 (14) ◽  
pp. 98
Author(s):  
Oluomachi Charity Nnachi ◽  
Robert Azu Nnachi ◽  
Innocent Paul Ezenwenyi ◽  
Ogah Emeka Onwe ◽  
Augustine Ejike Okoye ◽  
...  

Objective: Myeloid sarcoma is a rare form of acute myeloid leukaemia characterized by extramedullary proliferation of myeloid blasts which can occur as an isolated lesion in any organ. Even rarer it may occur in the orbit as the initial presentation without a leukaemic phase and diagnosis may be challenging when it is not suspected.           Methods: We report a case of orbital myeloid sarcoma as the initial presentation of acute myeloid leukaemia in an adult who was misdiagnosed and treated as a case of a pseudotumour with resultant significant disease progression and worsening of the clinical condition. There was a lag of four months from the onset of eye mass to the development of acute myeloid leukaemia. Result: Due to patients worsening condition and tumour progression, a repeat biopsy for a second histology opinion at a different facility, immunophenotyping and immunohistochemistry were employed to arrive at the correct diagnosis. Following chemotherapy, the orbital mass reduced markedly and clinical condition improved. The patient was indigent and could not sustain further funding of his treatment because he had already spent much on for management of complications he developed before a definitive diagnosis could be made. Conclusion: Myeloid sarcoma can present as an orbital mass without a leukemic disease. Therefore a high index of suspicion, meticulous examination of biopsy, immunohistochemistry and collaboration between oncologists and ophthalmologists, are required to arrive at an early accurate diagnosis.



2013 ◽  
Vol 127 (4) ◽  
pp. 415-418 ◽  
Author(s):  
C-L Kuo ◽  
Y-B Yu ◽  
W-Y Li ◽  
Y-L Lee

AbstractObjective:We report a rare case of concurrent myeloid sarcoma and acute fulminant invasive fungal sinusitis in a patient with relapsed acute myeloid leukaemia.Case report:A 73-year-old man was diagnosed with acute myeloid leukaemia and developed relapse one year later. After two courses of azacytidine, he began suffering from a dull pain in the left temporal and orbital regions. Sinus computed tomography showed a localised lesion in the left ethmoid sinus, which rapidly progressed to an extensive intracranial mass within one month. Surgical debridement was performed, and histopathological analysis revealed the coexistence of myeloid sarcoma and acute fulminant invasive fungal sinusitis. The patient responded well to prompt surgical debridement, antifungal medication and radiotherapy.Conclusion:Coexistence of sinonasal myeloid sarcoma and acute fulminant invasive fungal sinusitis poses an urgent diagnostic and management challenge to clinicians. Timely recognition of this rare comorbid condition is warranted as application of appropriate treatment can save lives.



Chemotherapy ◽  
2021 ◽  
pp. 1-5
Author(s):  
Salvatore Perrone ◽  
Elettra Ortu La Barbera ◽  
Federica Viola ◽  
Elena Cipollone ◽  
Maria Cristina Scerpa ◽  
...  

A patient with a therapy-related acute myeloid leukaemia (AML), NPM1<sup>mut</sup>, and FLT3-ITD+ was treated with induction and consolidation with CPX-351, obtaining a complete response (CR) but minimal residual disease persisted positive. Later, she complained progressive burning leg pain, weakening of the right hand and leg muscles, associated with absence of osteotendinous leg reflexes. Examination of cerebrospinal fluid (CSF) showed a meningeal relapse of AML. Moreover, a magnetic resonance imaging (MRI) showed 2 right meningeal implants of myeloid sarcoma and bone marrow revealed haematologic relapse of disease. She was treated with medicated lumbar punctures (LPs) followed by an FLA-Ida scheme, and she achieved a 2nd CR. Unfortunately, the patient developed hyperleucocytosis and reappearance of meningeal myeloid sarcoma at MRI. For this reason, a monotherapy with gilteritinib (an FLT3 inhibitor) was started: after 3 months of therapy, central nervous system (CNS)-disease shrunken and then faded, while AML in the bone marrow achieved only a partial response. This is the 1st report of a positive biological effect of gilteritinib on CNS (meningeal) myeloid sarcoma. There are no studies of gilteritinib concentration into CSF and penetration of gilteritinib into the blood-brain barrier should be further studied, given the paucity of drugs active on CNS relapse of AML. In patients receiving CPX-351 only, diagnostic LP should be considered after induction.





Pathology ◽  
2019 ◽  
Vol 51 (4) ◽  
pp. 441-443
Author(s):  
Laurence Galea ◽  
Chin-Guan Tan ◽  
Peter I.A. McQuillan ◽  
Sant Khan ◽  
Christopher Mow


2006 ◽  
Vol 7 (4) ◽  
pp. 350-352 ◽  
Author(s):  
Niccolò Bolli ◽  
Sara Galimberti ◽  
Maria P Martelli ◽  
Alessia Tabarrini ◽  
Giovanni Roti ◽  
...  


2010 ◽  
Vol 4 (2) ◽  
pp. 132-135 ◽  
Author(s):  
Mattheos K. Papamanthos ◽  
Alexandros E. Kolokotronis ◽  
Haralampos E. Skulakis ◽  
Angela-Monika A. Fericean ◽  
Matina T. Zorba ◽  
...  


2018 ◽  
pp. bcr-2017-222718 ◽  
Author(s):  
Rodrigo Athayde Nemésio ◽  
Beatriz Costa ◽  
Carlos Abrantes ◽  
Júlio Soares Leite


Sign in / Sign up

Export Citation Format

Share Document